Cargando…
MEDB-85. Transcriptional complexes as resistance drivers to BET inhibition
BET-bromodomain inhibition (BETi) is a promising therapeutic strategy to target MYC-driven cancers, including Group 3 medulloblastoma, a deadly childhood brain tumor. We have shown that BET inhibitors exhibit preclinical efficacy against MYC¬-amplified medulloblastoma, providing motivation to evalua...
Autores principales: | Boynton, Adam, Lupien, Leslie, Kumbhani, Rushil, Gionet, Gabrielle, Chacon, Madison, Goodale, Amy, Root, David, Keshishian, Hasmik, Robinson, Margaret, Carr, Steven, Bandopadhayay, Pratiti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164907/ http://dx.doi.org/10.1093/neuonc/noac079.459 |
Ejemplares similares
-
MEDB-73. Lipid metabolism as a therapeutic vulnerability in BET inhibitor-resistant medulloblastoma
por: Lupien, Leslie, et al.
Publicado: (2022) -
MEDB-45. Functional genomics identifies epigenetic regulators as novel therapeutic targets for sonic hedgehog medulloblastoma
por: Tsiami, Foteini, et al.
Publicado: (2022) -
MEDB-64. Are Rab GTPases metastatic drivers in metastatic medulloblastoma?
por: Entwistle, Susannah, et al.
Publicado: (2022) -
MEDB-57.GNAS inactivation as a driver for sonic hedgehog-activated medulloblastoma
por: Goode, Erin, et al.
Publicado: (2022) -
MEDB-33. The landscape of ecDNA in medulloblastoma
por: Chapman, Owen, et al.
Publicado: (2022)